Login to Your Account



China's Canbridge nabs Puma's Nerlynx for HER2+ breast cancer in $70M deal

By Shannon Ellis
Staff Writer

Wednesday, February 7, 2018

SHANGHAI – Beijing's Canbridge Life Sciences Inc. has acquired the greater China rights to Puma Biotechnology Inc.'s Nerlynx (neratinib) as an adjuvant for early stage HER2-positive breast cancer and other HER2 tumors, such as gastric cancer, which is highly prevalent in China.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription